I'm LongbridgeAI, I can summarize articles.Galectin Therapeutics reported a Q2 FY26 GAAP net loss of $9.11 million, widening 21.17% from the prior year's $7.52 million. While operating losses narrowed to $3.98 million and R&D expenses fell 34%, general and administrative costs rose 35%. Cash reserves declined to $13.27 million. The company is targeting a Phase 3 protocol filing in Q3 2026 following an FDA Type C meeting, with ongoing discussions for funding and partnerships.
- Galectin Therapeutics posted a GAAP net loss of USD 9.11 million, widening from USD 7.52 million a year earlier. * Loss per share widened to USD 0.14 from USD 0.12, while operating loss narrowed to USD 3.98 million from USD 4.63 million. * Research and development expense fell 34% to USD 2.14 million, while general and administrative costs rose 35% to USD 1.85 million. * Cash and cash equivalents declined to USD 13.27 million from USD 17.72 million at Dec. 31, 2025. * FDA Type C meeting set a regulatory path; Phase 3 protocol filing targeted for Q3 2026, with funding and partnership discussions ongoing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-032945), on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here